Survey and Research Archives | Page 7 of 98 | Be Korea-savvy

Archive by category Survey and Research

Europe needs €1.5 trillion to make urban mobility sustainable before 2050

Europe needs €1.5 trillion to make urban mobility sustainable before 2050

BARCELONA, Spain, Oct. 09, 2024 (Korea Bizwire) – European cities will need €1.5 trillion investment in sustainable mobility measures to meet the EU’s Green Deal emissions objectives by 2025. This is the main conclusion of the study “Cost and Benefit of the Urban Mobility Transition”, conducted by the EIT Urban Mobility, an initiative of the European [...]

World Economic Forum recognizes Schneider Electric Shanghai, China and Monterrey, Mexico factories as new Lighthouses

World Economic Forum recognizes Schneider Electric Shanghai, China and Monterrey, Mexico factories as new Lighthouses

Monterrey 1 new Advanced Lighthouse and Shanghai new End-to-End Value Chain Lighthouse, the company now has seven factories that have achieved Lighthouse statusThese are leading examples of how Fourth Industrial Revolution technologies can be leveraged for better sustainability and operational results Rueil-Malmaison, France, Oct. 08, 2024 (Korea Bizwire) – Schneider Electric, the leader in the digital [...]

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Prolia® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such [...]

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II  study1 Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis, and LIVERAGE-Cirrhosis in those with [...]

Personalization Powers Holiday Sales Surge, But 69% of Shoppers Plan Spending Cuts in 2025

Personalization Powers Holiday Sales Surge, But 69% of Shoppers Plan Spending Cuts in 2025

New consumer research reveals that while 37% of shoppers are buying more frequently due to personalized recommendations, a significant pullback is expected next year BOSTON, Oct. 02, 2024 (Korea Bizwire) – As brands and retailers race through the busiest quarter of the year, Salsify and the Digital Shelf Institute’s (DSI) Ecommerce Pulse Report offers critical insights into [...]

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphoma SALT LAKE CITY, Oct. 02, [...]

Token 2049’s Spotlight: Asia Leads the Race for the First DeSci Unicorn

Token 2049’s Spotlight: Asia Leads the Race for the First DeSci Unicorn

SINGAPORE, Oct. 01, 2024 (Korea Bizwire) – At the event “How to Pinpoint the First DeSci Unicorn?” held on September 17, 2024, in Singapore during Token 2049, top renowned tech leaders and investors gathered to discuss the future of decentralized science (DeSci). Led by Dr. Tuan Cao, founder of LIFE AI; Matthew Immerso, Head of [...]

Verisk Estimates Industry Insured Losses from Flooding in Central Europe to Range from EUR 2 Billion (~USD 2.2 Billion) to EUR 3 Billion (~USD 3.4 Billion)

Verisk Estimates Industry Insured Losses from Flooding in Central Europe to Range from EUR 2 Billion (~USD 2.2 Billion) to EUR 3 Billion (~USD 3.4 Billion)

BOSTON, Oct. 01, 2024 (Korea Bizwire) – The Extreme Event Solutions group at Verisk (Nasdaq: VRSK), a leading global data analytics and technology provider, estimates that insured industry losses from the flooding in Czechia, Poland and Austria in September 2024 will range from EUR 2 billion (~USD 2.2 billion) to EUR 3 billion (~USD 3.4 [...]

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update

DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update

Additional clinical data on patients suffering from Obstructive Sleep Apnea (OSA) demonstrate a clinically significant 71.0% median reduction in Apnea-Hypopnea index (AHI) while sleeping supine at 12 months compared with baseline. 82.0% of patients who completed a polysomnography at 12 months had an AHI below 15, and 67.4% of patients who completed a polysomnography at 12 [...]

Publication relating to transparency notifications: Nyxoah

Publication relating to transparency notifications: Nyxoah

Mont-Saint-Guibert (Belgium), September 27, 2024, 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On September 24, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons [...]